Compare Tango Therapeutics Inc. (TNGX) vs Targa Resources Inc. Common Stock (TRGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Targa Resources Inc. Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Targa Resources Inc. Common Stock trades at $290.9 (market cap $62.84B). The key difference: Targa Resources Inc. Common Stock is far larger — about 16.8× Tango Therapeutics Inc.'s market cap, and Targa Resources Inc. Common Stock pays a 1.71% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Targa Resources Inc. Common Stock for 5 Days on average.
| TNGX | TRGP | |
|---|---|---|
Market Cap | $3.75B | $62.84B |
Volume | 9,619,106 | 654,800 |
Sector | Health | Energy |
52-Week High | $32.90 | $302.25 |
52-Week Low | $7.50 | $146.30 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $2.77B | $82.28B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
TRGP trades at $293.04, up 0.86% today, with a bullish technical signal driven by moving averages and a consensus analyst price target of $329.54. The company reported strong Q2 2026 EPS of $3.54, beating expectations, and maintains robust profitability with a net income margin of 13.54% and ROE of 72.27%. Recent news highlights a $1.25 quarterly dividend and sustainability reporting, reflecting stable operations.
The outlook is positive given earnings beats, high analyst buy ratings (82%), and projected revenue growth, though risks include commodity price exposure and high debt-to-asset ratio of 68.07%. The stock's current price near the analyst low target of $294.00 suggests potential upside if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Targa Resources Inc. Common Stock
Targa Resources provides midstream infrastructure for natural gas and natural gas liquids. Its services include gathering, processing, transportation, fractionation, storage, and export logistics.
Read more on TRGP →
